Researchers identify brain receptor that could reduce neuroinflammation in Alzheimer's disease
Scientists studying human brain tissue discovered that blocking the P2X7 receptor significantly reduces inflammatory responses associated with Alzheimer's disease, Parkinson's disease, and traumatic brain injury. The research, conducted using live brain cell cultures and surgical tissue samples, demonstrated that this receptor drives the release of inflammatory proteins called cytokines. The findings suggest an existing drug could potentially be repurposed to target neuroinflammation at its source across multiple brain disorders.
The research team employed an innovative methodology to overcome long-standing obstacles in neurological research. They developed a technique to transform human blood cells into microglia—the brain's primary immune regulators—allowing them to study inflammatory processes in a controlled setting. This approach proved valuable because microglia typically lose their functional properties when isolated from brain tissue, making direct study difficult.
The scientists validated their findings by progressing from laboratory cell cultures to actual human brain samples obtained during surgical procedures. By demonstrating that P2X7 receptor blocking reduces inflammatory protein release in both settings, they established that the mechanism works in realistic tissue conditions, strengthening the case for therapeutic development targeting this pathway across multiple neurological conditions.
If validated through clinical trials, blocking the P2X7 receptor could affect millions of patients with Alzheimer's, Parkinson's, and traumatic brain injuries by potentially slowing neuroinflammatory damage. The approach may also benefit individuals with depression and other psychiatric conditions increasingly linked to brain inflammation. Since the research suggests using an existing drug rather than developing a new one, translation to clinical use could proceed faster and potentially at lower cost, though significant testing remains necessary before patient applications.